From Cancer Therapy Advisor:
Treating TKI-induced Hypertension in Renal Cell Carcinoma
Those with advanced kidney cancer may be treated with tyrosine kinase inhibitors (TKIs) that block vascular endothelial growth factor receptors (VEGFR); these agents include sorafenib, sunitinib, pazopanib, cabozantinib, axitinib, and lenvatinib. Inhibiting the VEGF signaling pathway can cause hypertension in patients treated with these agents. Although this adverse event is widely observed, there are limited data on managing kinase inhibitor-induced hypertension.
Read the full article.